Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

Henrik Sillesen; Gregory Albers; Irfan Altafullah; Oscar Benavente; Diane Book; Joseph Broderick; Christopher Calder; Alfred S. Callahan; Walter Carlini; Seemant Chaturvedi; Thomas Chippendale; Wayne Clark; Greg Collins; Bruce Coull; Patricia Davis; Thomas Devlin; Arthur R. Dick; Lucy Younger Dirr-Ledbetter; George Dooneief; R. Scott Duff; Nordeli Estronza; Alejandro Forteza; Michael R. Frankel; James L. Frey; Gary Friday; Jerome Goldstein; Steven Goldstein; Gleen Graham; Wayne Harper; Jonathan Harris; Barry Hendin; David C. Hess; Richard Hinton; Joshua Hollander; Chung Y. Hsu; Richard L. Hughes; Scott Kasner; T. A. Kent; Lance Kim; Howard Kirshner; Marian LaMonte; Kenneth Levin; Richard Libman; Paul McDowell; Francis E. McGee; Brett Meyer; Alireza Minagar; Frederick E. Munschauer; Richard Munson; Marshall Nash; Sean C. Orr; Gerald Ratinov; Virgilio Salanga; Souvik Sen; Scott Silliman; Richard Singer; Don Smith; Herman Sullivan; David Thaler; Gretchen Tietjen; Michael Tuchman; David Uskavitch; Piero Verro; Ralph Vicari; Richard Weinstein; Janet Wilterdink; Richard Zweifler; Michael Beaudry; Robert Cote; Keith Hoyte; Louise Helene Lebrun; John Norris; Daniel Selchen; Ashfaq Shuaib; Denis Simard; David Spence; Philip Teal; Michael Winger; Reinhold Schmidt; Bruno Pramsohler; Christoph Schmidauer; Markku Kaste; Juhani Sivenius; Anna Wagner; Andreas Terent; Pierre Amarenco; Loic Milandre; Francois Chollet; Thomas de Broucker; Thierry Moulin; Etienne Roullet; Didier Leys; Marie Helene Mahagne; Michael Hennerici; W. D. Heiss; Otto Busse; Roman Haberl; L. Harms; C. Diener; G. Hamann; E. Bemd Ringelstein; Nicola Canal; Antonio Capurso; Angelo Mamoli; Lodovico Frattola; Carlo Gandolfo; Umberto Senin; Michele Zito; Keyser de Keyser; The Netherlands; P. J. Koudstaal; J. A. Haas; G. de Jong; Julien Bogousslavsky; Heinrich Mattie; Ralf Baumgartner; R. S. MacWalter; Roelfe Dijkhuizen; Enefioke Ben Ekpo; Philip Bath; Kennedy R. Lees; Jose Ferro; Luis Cunha; Antonio Davalos; Angel Chamorro; Alvarez Sabin; Dolores Jimenez; Jose Ramon Gonzalez; Aida Lago; Jose Egido; Jose Vivancos; Matias Guiu; Geoffrey Dorman; Stephen Davis; David Gilles; Judy Frayne; Denis Crimmins; Simon Dimmit; Gagrath Pradeep Singh; Russell Scott; Neil Edward Anderson; J. Carr; A. K. Kruger; J. Gardiner

doi:10.1159/000072562

Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

Henrik Sillesen, Gregory Albers, Irfan Altafullah, Oscar Benavente, Diane Book, Joseph Broderick, Christopher Calder, Alfred S. Callahan, Walter Carlini, Seemant Chaturvedi, Thomas Chippendale, Wayne Clark, Greg Collins, Bruce Coull, Patricia Davis, Thomas Devlin, Arthur R. Dick, Lucy Younger Dirr-Ledbetter, George Dooneief, R. Scott DuffNordeli Estronza, Alejandro Forteza, Michael R. Frankel, James L. Frey, Gary Friday, Jerome Goldstein, Steven Goldstein, Gleen Graham, Wayne Harper, Jonathan Harris, Barry Hendin, David C. Hess, Richard Hinton, Joshua Hollander, Chung Y. Hsu, Richard L. Hughes, Scott Kasner, T. A. Kent, Lance Kim, Howard Kirshner, Marian LaMonte, Kenneth Levin, Richard Libman, Paul McDowell, Francis E. McGee, Brett Meyer, Alireza Minagar, Frederick E. Munschauer, Richard Munson, Marshall Nash, Sean C. Orr, Gerald Ratinov, Virgilio Salanga, Souvik Sen, Scott Silliman, Richard Singer, Don Smith, Herman Sullivan, David Thaler, Gretchen Tietjen, Michael Tuchman, David Uskavitch, Piero Verro, Ralph Vicari, Richard Weinstein, Janet Wilterdink, Richard Zweifler, Michael Beaudry, Robert Cote, Keith Hoyte, Louise Helene Lebrun, John Norris, Daniel Selchen, Ashfaq Shuaib, Denis Simard, David Spence, Philip Teal, Michael Winger, Reinhold Schmidt, Bruno Pramsohler, Christoph Schmidauer, Markku Kaste, Juhani Sivenius, Anna Wagner, Andreas Terent, Pierre Amarenco, Loic Milandre, Francois Chollet, Thomas de Broucker, Thierry Moulin, Etienne Roullet, Didier Leys, Marie Helene Mahagne, Michael Hennerici, W. D. Heiss, Otto Busse, Roman Haberl, L. Harms, C. Diener, G. Hamann, E. Bemd Ringelstein, Nicola Canal, Antonio Capurso, Angelo Mamoli, Lodovico Frattola, Carlo Gandolfo, Umberto Senin, Michele Zito, Keyser de Keyser, The Netherlands, P. J. Koudstaal, J. A. Haas, G. de Jong, Julien Bogousslavsky, Heinrich Mattie, Ralf Baumgartner, R. S. MacWalter, Roelfe Dijkhuizen, Enefioke Ben Ekpo, Philip Bath, Kennedy R. Lees, Jose Ferro, Luis Cunha, Antonio Davalos, Angel Chamorro, Alvarez Sabin, Dolores Jimenez, Jose Ramon Gonzalez, Aida Lago, Jose Egido, Jose Vivancos, Matias Guiu, Geoffrey Dorman, Stephen Davis, David Gilles, Judy Frayne, Denis Crimmins, Simon Dimmit, Gagrath Pradeep Singh, Russell Scott, Neil Edward Anderson, J. Carr, A. K. Kruger, J. Gardiner

Research output: Contribution to journal › Article › peer-review

161 Scopus citations

Abstract

Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.

Original language	English (US)
Pages (from-to)	389-395
Number of pages	7
Journal	Cerebrovascular Diseases
Volume	16
Issue number	4
DOIs	https://doi.org/10.1159/000072562
State	Published - 2003
Externally published	Yes

Keywords

Atorvastatin
Cholesterol
Lipid
Statin
Stroke

ASJC Scopus subject areas

Neurology
Clinical Neurology
Cardiology and Cardiovascular Medicine

Access to Document

10.1159/000072562

Cite this

Sillesen, H., Albers, G., Altafullah, I., Benavente, O., Book, D., Broderick, J., Calder, C., Callahan, A. S., Carlini, W., Chaturvedi, S., Chippendale, T., Clark, W., Collins, G., Coull, B., Davis, P., Devlin, T., Dick, A. R., Dirr-Ledbetter, L. Y., Dooneief, G., ... Gardiner, J. (2003). Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovascular Diseases, 16(4), 389-395. https://doi.org/10.1159/000072562

Sillesen, H, Albers, G, Altafullah, I, Benavente, O, Book, D, Broderick, J, Calder, C, Callahan, AS, Carlini, W, Chaturvedi, S, Chippendale, T, Clark, W, Collins, G, Coull, B, Davis, P, Devlin, T, Dick, AR, Dirr-Ledbetter, LY, Dooneief, G, Duff, RS, Estronza, N, Forteza, A, Frankel, MR, Frey, JL, Friday, G, Goldstein, J, Goldstein, S, Graham, G, Harper, W, Harris, J, Hendin, B, Hess, DC, Hinton, R, Hollander, J, Hsu, CY, Hughes, RL, Kasner, S, Kent, TA, Kim, L, Kirshner, H, LaMonte, M, Levin, K, Libman, R, McDowell, P, McGee, FE, Meyer, B, Minagar, A, Munschauer, FE, Munson, R, Nash, M, Orr, SC, Ratinov, G, Salanga, V, Sen, S, Silliman, S, Singer, R, Smith, D, Sullivan, H, Thaler, D, Tietjen, G, Tuchman, M, Uskavitch, D, Verro, P, Vicari, R, Weinstein, R, Wilterdink, J, Zweifler, R, Beaudry, M, Cote, R, Hoyte, K, Lebrun, LH, Norris, J, Selchen, D, Shuaib, A, Simard, D, Spence, D, Teal, P, Winger, M, Schmidt, R, Pramsohler, B, Schmidauer, C, Kaste, M, Sivenius, J, Wagner, A, Terent, A, Amarenco, P, Milandre, L, Chollet, F, de Broucker, T, Moulin, T, Roullet, E, Leys, D, Mahagne, MH, Hennerici, M, Heiss, WD, Busse, O, Haberl, R, Harms, L, Diener, C, Hamann, G, Ringelstein, EB, Canal, N, Capurso, A, Mamoli, A, Frattola, L, Gandolfo, C, Senin, U, Zito, M, de Keyser, K, Netherlands, T, Koudstaal, PJ, Haas, JA, de Jong, G, Bogousslavsky, J, Mattie, H, Baumgartner, R, MacWalter, RS, Dijkhuizen, R, Ekpo, EB, Bath, P, Lees, KR, Ferro, J, Cunha, L, Davalos, A, Chamorro, A, Sabin, A, Jimenez, D, Gonzalez, JR, Lago, A, Egido, J, Vivancos, J, Guiu, M, Dorman, G, Davis, S, Gilles, D, Frayne, J, Crimmins, D, Dimmit, S, Singh, GP, Scott, R, Anderson, NE, Carr, J, Kruger, AK & Gardiner, J 2003, 'Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study', Cerebrovascular Diseases, vol. 16, no. 4, pp. 389-395. https://doi.org/10.1159/000072562

@article{3580e1197c194220b8f6615a8311b758,

title = "Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study",

abstract = "Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.",

keywords = "Atorvastatin, Cholesterol, Lipid, Statin, Stroke",

author = "Henrik Sillesen and Gregory Albers and Irfan Altafullah and Oscar Benavente and Diane Book and Joseph Broderick and Christopher Calder and Callahan, {Alfred S.} and Walter Carlini and Seemant Chaturvedi and Thomas Chippendale and Wayne Clark and Greg Collins and Bruce Coull and Patricia Davis and Thomas Devlin and Dick, {Arthur R.} and Dirr-Ledbetter, {Lucy Younger} and George Dooneief and Duff, {R. Scott} and Nordeli Estronza and Alejandro Forteza and Frankel, {Michael R.} and Frey, {James L.} and Gary Friday and Jerome Goldstein and Steven Goldstein and Gleen Graham and Wayne Harper and Jonathan Harris and Barry Hendin and Hess, {David C.} and Richard Hinton and Joshua Hollander and Hsu, {Chung Y.} and Hughes, {Richard L.} and Scott Kasner and Kent, {T. A.} and Lance Kim and Howard Kirshner and Marian LaMonte and Kenneth Levin and Richard Libman and Paul McDowell and McGee, {Francis E.} and Brett Meyer and Alireza Minagar and Munschauer, {Frederick E.} and Richard Munson and Marshall Nash and Orr, {Sean C.} and Gerald Ratinov and Virgilio Salanga and Souvik Sen and Scott Silliman and Richard Singer and Don Smith and Herman Sullivan and David Thaler and Gretchen Tietjen and Michael Tuchman and David Uskavitch and Piero Verro and Ralph Vicari and Richard Weinstein and Janet Wilterdink and Richard Zweifler and Michael Beaudry and Robert Cote and Keith Hoyte and Lebrun, {Louise Helene} and John Norris and Daniel Selchen and Ashfaq Shuaib and Denis Simard and David Spence and Philip Teal and Michael Winger and Reinhold Schmidt and Bruno Pramsohler and Christoph Schmidauer and Markku Kaste and Juhani Sivenius and Anna Wagner and Andreas Terent and Pierre Amarenco and Loic Milandre and Francois Chollet and {de Broucker}, Thomas and Thierry Moulin and Etienne Roullet and Didier Leys and Mahagne, {Marie Helene} and Michael Hennerici and Heiss, {W. D.} and Otto Busse and Roman Haberl and L. Harms and C. Diener and G. Hamann and Ringelstein, {E. Bemd} and Nicola Canal and Antonio Capurso and Angelo Mamoli and Lodovico Frattola and Carlo Gandolfo and Umberto Senin and Michele Zito and {de Keyser}, Keyser and The Netherlands and Koudstaal, {P. J.} and Haas, {J. A.} and {de Jong}, G. and Julien Bogousslavsky and Heinrich Mattie and Ralf Baumgartner and MacWalter, {R. S.} and Roelfe Dijkhuizen and Ekpo, {Enefioke Ben} and Philip Bath and Lees, {Kennedy R.} and Jose Ferro and Luis Cunha and Antonio Davalos and Angel Chamorro and Alvarez Sabin and Dolores Jimenez and Gonzalez, {Jose Ramon} and Aida Lago and Jose Egido and Jose Vivancos and Matias Guiu and Geoffrey Dorman and Stephen Davis and David Gilles and Judy Frayne and Denis Crimmins and Simon Dimmit and Singh, {Gagrath Pradeep} and Russell Scott and Anderson, {Neil Edward} and J. Carr and Kruger, {A. K.} and J. Gardiner",

year = "2003",

doi = "10.1159/000072562",

language = "English (US)",

volume = "16",

pages = "389--395",

journal = "Cerebrovascular Diseases",

issn = "1015-9770",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

AU - Sillesen, Henrik

AU - Albers, Gregory

AU - Altafullah, Irfan

AU - Benavente, Oscar

AU - Book, Diane

AU - Broderick, Joseph

AU - Calder, Christopher

AU - Callahan, Alfred S.

AU - Carlini, Walter

AU - Chaturvedi, Seemant

AU - Chippendale, Thomas

AU - Clark, Wayne

AU - Collins, Greg

AU - Coull, Bruce

AU - Davis, Patricia

AU - Devlin, Thomas

AU - Dick, Arthur R.

AU - Dirr-Ledbetter, Lucy Younger

AU - Dooneief, George

AU - Duff, R. Scott

AU - Estronza, Nordeli

AU - Forteza, Alejandro

AU - Frankel, Michael R.

AU - Frey, James L.

AU - Friday, Gary

AU - Goldstein, Jerome

AU - Goldstein, Steven

AU - Graham, Gleen

AU - Harper, Wayne

AU - Harris, Jonathan

AU - Hendin, Barry

AU - Hess, David C.

AU - Hinton, Richard

AU - Hollander, Joshua

AU - Hsu, Chung Y.

AU - Hughes, Richard L.

AU - Kasner, Scott

AU - Kent, T. A.

AU - Kim, Lance

AU - Kirshner, Howard

AU - LaMonte, Marian

AU - Levin, Kenneth

AU - Libman, Richard

AU - McDowell, Paul

AU - McGee, Francis E.

AU - Meyer, Brett

AU - Minagar, Alireza

AU - Munschauer, Frederick E.

AU - Munson, Richard

AU - Nash, Marshall

AU - Orr, Sean C.

AU - Ratinov, Gerald

AU - Salanga, Virgilio

AU - Sen, Souvik

AU - Silliman, Scott

AU - Singer, Richard

AU - Smith, Don

AU - Sullivan, Herman

AU - Thaler, David

AU - Tietjen, Gretchen

AU - Tuchman, Michael

AU - Uskavitch, David

AU - Verro, Piero

AU - Vicari, Ralph

AU - Weinstein, Richard

AU - Wilterdink, Janet

AU - Zweifler, Richard

AU - Beaudry, Michael

AU - Cote, Robert

AU - Hoyte, Keith

AU - Lebrun, Louise Helene

AU - Norris, John

AU - Selchen, Daniel

AU - Shuaib, Ashfaq

AU - Simard, Denis

AU - Spence, David

AU - Teal, Philip

AU - Winger, Michael

AU - Schmidt, Reinhold

AU - Pramsohler, Bruno

AU - Schmidauer, Christoph

AU - Kaste, Markku

AU - Sivenius, Juhani

AU - Wagner, Anna

AU - Terent, Andreas

AU - Amarenco, Pierre

AU - Milandre, Loic

AU - Chollet, Francois

AU - de Broucker, Thomas

AU - Moulin, Thierry

AU - Roullet, Etienne

AU - Leys, Didier

AU - Mahagne, Marie Helene

AU - Hennerici, Michael

AU - Heiss, W. D.

AU - Busse, Otto

AU - Haberl, Roman

AU - Harms, L.

AU - Diener, C.

AU - Hamann, G.

AU - Ringelstein, E. Bemd

AU - Canal, Nicola

AU - Capurso, Antonio

AU - Mamoli, Angelo

AU - Frattola, Lodovico

AU - Gandolfo, Carlo

AU - Senin, Umberto

AU - Zito, Michele

AU - de Keyser, Keyser

AU - Netherlands, The

AU - Koudstaal, P. J.

AU - Haas, J. A.

AU - de Jong, G.

AU - Bogousslavsky, Julien

AU - Mattie, Heinrich

AU - Baumgartner, Ralf

AU - MacWalter, R. S.

AU - Dijkhuizen, Roelfe

AU - Ekpo, Enefioke Ben

AU - Bath, Philip

AU - Lees, Kennedy R.

AU - Ferro, Jose

AU - Cunha, Luis

AU - Davalos, Antonio

AU - Chamorro, Angel

AU - Sabin, Alvarez

AU - Jimenez, Dolores

AU - Gonzalez, Jose Ramon

AU - Lago, Aida

AU - Egido, Jose

AU - Vivancos, Jose

AU - Guiu, Matias

AU - Dorman, Geoffrey

AU - Davis, Stephen

AU - Gilles, David

AU - Frayne, Judy

AU - Crimmins, Denis

AU - Dimmit, Simon

AU - Singh, Gagrath Pradeep

AU - Scott, Russell

AU - Anderson, Neil Edward

AU - Carr, J.

AU - Kruger, A. K.

AU - Gardiner, J.

PY - 2003

Y1 - 2003

N2 - Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.

AB - Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4,732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.

KW - Atorvastatin

KW - Cholesterol

KW - Lipid

KW - Statin

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0141676273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141676273&partnerID=8YFLogxK

U2 - 10.1159/000072562

DO - 10.1159/000072562

M3 - Article

C2 - 14584489

AN - SCOPUS:0141676273

VL - 16

SP - 389

EP - 395

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 4

ER -

Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this